Change in cognition ‐ not investigated · Apathy in people with mild‐to‐moderate Alzheimer's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in functional performance · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Change in global disease severity ‐ not investigated · Apathy in people with mild‐to‐moderate Alzheimer's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dropouts ‐ reported, but not analyzed in this review · Apathy in people with mild‐to‐moderate Alzheimer's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Apathy in people with mild‐to‐moderate Alzheimer's disease
Methylphenidate showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Change in NPS · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Change in cognition · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Change in functional performance · Apathy in people with mild‐to‐moderate Alzheimer's disease
2 findings from 1 review
Change in global disease severity · Apathy in people with mild‐to‐moderate Alzheimer's disease
Methylphenidate showed no clear difference in change in global disease severity compared with placebo (moderate certainty).
1 finding from 1 review
Leaving the study early · Apathy in people with mild‐to‐moderate Alzheimer's disease
Methylphenidate showed no clear difference in dropouts compared with placebo (low certainty).
1 finding from 1 review
Duration of delirium Days · people with delirium
1 finding from 1 review
Severity of delirium CAM negative · people with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: nausea · people with delirium
Cholinesterase inhibitors (rivastigmine) showed no clear difference in adverse events nausea compared with placebo (low certainty).
1 finding from 1 review
Persistent cognitive impairment · people with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · people with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with delirium
Cholinesterase inhibitors (rivastigmine) showed no clear difference in mortality compared with placebo (low certainty).
1 finding from 1 review
Cost of the intervention · people with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in ADAS‐Cog · people with Alzheimer's disease
1 finding from 1 review
Number of participants experiencing any serious adverse events · people with Alzheimer's disease
Vitamin E (capsules 2000 IU/day in two divided doses) showed no clear difference in adverse events Number of participants reporting ≥ 1 serious adverse… compared with placebo (moderate certainty).
1 finding from 1 review
Deaths Number of deaths · people with Alzheimer's disease
Vitamin E (capsules 2000 IU/day in two divided doses) showed no clear difference in deaths Number of deaths compared with placebo (moderate certainty).
1 finding from 1 review